10 completed, 5 recruiting, 4 terminated, 1 active not recruiting. 22 Phase 1, 9 Phase 2.
Follow Hematological Malignancy: new trials by email Literature Review of Hematological Malignancy trials Research Report on Hematological Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies MEN2312 - Hematological Malignancy | Phase 1 / Phase 2 | Not yet recruiting | Stemline Therapeutics, Inc. | 115 | 2026-10-30 | 2026-10-14 |
| Study to Evaluate the Safety and Effectiveness of Withaferin A as a Treatment to Prevent GvHD in Transplant Patients SWA (standardized root extract of Withania somnifera) - Hematopoietic Stem Cell Transplant (HSCT), GVHD - Graft-Versus-Host Disease | Phase 1 / Phase 2 | Recruiting | Tata Memorial Centre | 54 | 2025-01-28 | 2026-07-24 |
| Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies CAR-T - Multiple Myeloma, B-cell Lymphoma | Phase 1 | Recruiting | The Third Affiliated Hospital of Southern Medical University | 60 | 2025-01-15 | 2025-01-06 |
| Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells - Hematological Malignancy | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 64 | 2024-04-22 | 2026-08-20 |
| An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies YY201 - Advanced Solid Tumor, Hematological Malignancy | Phase 1 | Recruiting | Shanghai Yuyao Biotech Co., Ltd. | 96 | 2023-10-26 | 2024-01-31 |
| A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007) Nemtabrutinib - Hematological Malignancy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 40 | 2023-08-28 | 2024-09-19 |
| First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors OT-A201, IMids, Bevacizumab - Hematological Malignancy, Solid Tumor | Phase 1 | Recruiting | Onward Therapeutics | 150 | 2023-07-10 | 2025-03-20 |
| SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma. SG2501 - Hematological Malignancy, Lymphoma | Phase 1 | Terminated | Hangzhou Sumgen Biotech Co., Ltd. | 2 | 2023-03-03 | 2025-03-18 |
| SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies SG301 - Relapsed or Refractory Multiple Myeloma, Hematological Malignancy | Phase 1 | Active not recruiting | Hangzhou Sumgen Biotech Co., Ltd. | 61 | 2021-11-04 | 2026-08-11 |
| Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies Pelabresib - Advanced Malignancies, Solid Tumor | Phase 1 | Completed | Constellation Pharmaceuticals | 35 | 2021-07-20 | 2025-07-28 |
| Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies ATG-017, ATG-017+Nivolumab - Solid Tumor, Hematological Malignancy | Phase 1 | Terminated | Antengene Therapeutics Limited | 36 | 2020-08-15 | 2024-07-23 |
| Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells Metoprolol, metoprolol, infliximab, etanercept, tocilizumab and/or other agents - Solid Tumor, Hematological Malignancy | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2019-09-15 | 2022-04-13 |
| VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies Cord blood stem cells, Valproic Acid, Fludarabine - Hematological Malignancy, Acute Leukemia in Remission | Phase 1 | Completed | Alla Keyzner | 7 | 2019-02-21 | 2021-05-24 |
| Body Scan Activity on Bone Marrow Transplant Patients and Their Caregivers Body Scan, Rotterdam Symptom Checklist, Practice Logs - Hematological Malignancy | Phase 1 | Terminated | Washington University School of Medicine | 37 | 2018-04-17 | 2018-10-31 |
| A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients isavuconazonium sulfate - intravenous, isavuconazonium sulfate - oral - Hematological Malignancy | Phase 1 | Completed | Astellas Pharma Global Development, Inc. | 49 | 2017-10-02 | 2024-11-19 |
| Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL MT-3724 Phase 1, MT-3724 Phase 2 - Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 / Phase 2 | Terminated | Molecular Templates, Inc. | 38 | 2015-02-01 | 2022-08-18 |
| Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation NK Cell infusion - Hematological Malignancy | Phase 1 | Completed | Institut Paoli-Calmettes | 17 | 2013-04-01 | 2026-04-21 |
| Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis Cohort 1-Bortezomib (Velcade ®), Cohort 2-Bortezomib (Velcade ®), Cohort 3-Bortezomib (Velcade ®) - Hematological Malignancy | Phase 1 / Phase 2 | Completed | Corewell Health West | 28 | 2012-04-01 | 2023-06-02 |
| A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy AlloStim - Hematological Malignancy, Leukemia | Phase 1 / Phase 2 | Completed | Mirror Biologics, Inc. | 6 | 2010-12-01 | 2020-01-22 |
| A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies Belinostat, Warfarin - Solid Tumor, Hematological Malignancy | Phase 1 | Completed | Spectrum Pharmaceuticals, Inc | 27 | 2010-12-01 | 2015-09-23 |
Showing 20 of 22. Sign in to see all of them.
Hematologic Neoplasms (22) · Lymphoma (4) · Leukemia (3) · Lymphoma, Non-Hodgkin (3) · Multiple Myeloma (3) · Recurrence (3) · Hodgkin Disease (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell (2) · Cytokine Release Syndrome (1) · Graft vs Host Disease (1) · Invasive Fungal Infections (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Large B-Cell, Diffuse (1)
Hematologic Diseases (22) · Hemic and Lymphatic Diseases (22) · Neoplasms by Site (22) · Neoplasms (21) · Immune System Diseases (7) · Neoplasms by Histologic Type (7) · Immunoproliferative Disorders (6) · Lymphoproliferative Disorders (6) · Lymphatic Diseases (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Disease Attributes (4) · Blood Protein Disorders (3) · Cardiovascular Diseases (3) · Hemorrhagic Disorders (3)
Cyclophosphamide (3) · fludarabine (2) · ARQ531 (1) · Antibodies, Bispecific (1) · Bevacizumab (1) · Bortezomib (1) · Dexamethasone (1) · Etanercept (1) · Immunomodulating Agents (1) · Infliximab (1) · Lenalidomide (1) · Metoprolol (1) · Paclitaxel (1) · Thiotepa (1) · Valproic Acid (1)
Hangzhou Sumgen Biotech Co., Ltd. (2) · Alla Keyzner (1) · Antengene Therapeutics Limited (1) · Assistance Publique - Hôpitaux de Paris (1) · Astellas Pharma Global Development, Inc. (1) · Chinese PLA General Hospital (1) · Constellation Pharmaceuticals (1) · Corewell Health West (1) · Institut Paoli-Calmettes (1) · M.D. Anderson Cancer Center (1) · Merck Sharp & Dohme LLC (1) · Mirror Biologics, Inc. (1) · Molecular Templates, Inc. (1) · Onward Therapeutics (1) · Sanofi (1)
United States (11) · China (4) · France (4) · Israel (3) · Spain (3) · Georgia (2) · Ukraine (2) · Argentina (1) · Australia (1) · Belarus (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · Finland (1)
A. Samer Al-Homsi, MD (1) · Alla Keyzner, MD (1) · Anupa Kudva, MD (1) · Dr. Michael Har-Noy (1) · Eric Raymond, MD, PhD (1) · Maggie Compernolle, BSN, RN (1) · Sai Lou, MD (1) · Sunil Sharma, MD, FACP (1) · Yan Yi, MD. (1) · Yiqiang Zhao, MD (1)
PMID 10845900, PMID 12663454, PMID 18997826, PMID 19282026, PMID 22410750, PMID 22754076, PMID 22982675, PMID 23802653, PMID 25452693, PMID 26408225, PMID 26959007, PMID 27250656, PMID 30904387, PMID 31678539, PMID 32160294, PMID 32409691, PMID 32416453, PMID 32537114, PMID 32684166, PMID 32718876, PMID 33080623, PMID 33574236, PMID 34031051, PMID 34071607, PMID 34204308, PMID 34464155, PMID 3513012, PMID 35432352, PMID 35488407, PMID 35798714, PMID 36059523, PMID 36477110, PMID 36518386, PMID 37774014, PMID 37883795, PMID 5449164, PMID 9746768